Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dosing of BRAK and MEK Inhibitors in Melanoma: No Point in Taking a Break.

Cancer cell - 14 Dec 2020

Lee Jenny H, Carlino Matteo S, Rizos Helen

Abstract excerpt

Resistance to BRAF/MEK inhibitor treatment occurs in most patients with advanced BRAFV600-mutant melanoma. Intermittent drug dosing had been proposed as a strategy to circumvent resistance. In a clinical trial published in Nature Medicine, continuous dosing of BRAF/MEK inhibitors produced superior progression-free survival compared to intermittent dosing in BRAFV600-mutant melanoma patients.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase II as Topic
Share to Disease-Free Survival
Share to Drug Administration Schedule

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Dosage Calculations

Share to Imidazoles

Share to Oximes

Share to Pyridones

Share to Pyrimidinones

Source

Identifiers

PMID: 33321086
DOI: 10.1016/j.ccell.2020.11.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dosing of BRAK and MEK Inhibitors in Melanoma: No Point in Taking a Break.PMID 33321086Read ↗

A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM).Semantic proximity Read ↗

Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial.Semantic proximity Read ↗

IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation.Semantic proximity Read ↗

Breaking resistance in BRAF-mutant Melanoma: Novel strategies and biomarkers for optimizing targeted therapies.Semantic proximity Read ↗

Long-Term Response to Intermittent Binimetinib in Patients with NRAS-Mutant Melanoma.Semantic proximity Read ↗

KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.Semantic proximity Read ↗

Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistanceSemantic proximity Read ↗

Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.Semantic proximity Read ↗

Intermittent treatment of BRAFV600E melanoma cells delays resistance by adaptive resensitization to drug rechallenge.Semantic proximity Read ↗

A new BRAF inhibitor breaks resistance barriers.Semantic proximity Read ↗

Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment Vulnerabilities.Semantic proximity Read ↗

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.